India, Nov. 15 -- Hansoh Pharmaceutical Group Co., Ltd. (HNSPF), a China-based pharmaceutical company, announced that the European Medicines Agency's CHMP adopted a positive opinion on November 12, 2026, recommending marketing authorization for Aumolertinib, branded Aumseqa outside China, for treating non-small cell lung cancer (NSCLC).
The positive opinion from CHMP represents a significant milestone in the regulatory pathway. However, the marketing authorization remains subject to final approval by the European Commission (EC).
The company said this recommendation follows its September 27 and October 11, 2026 announcements on Aumolertinib's EU marketing authorization status.
For comments and feedback contact: editorial@rttnews.com
Pub...